Skip to main content
Premium Trial:

Request an Annual Quote

Certara, Thomson Reuters Ink Data Access Agreement

Premium

Certara said this week that it is partnering with Thomson Reuters to provide customers of its D360 software solution with access to content contained in Thomson Reuters' Cortellis for Informatics system.

The D360 solution provides tools for pharmaceutical companies to query, analyze, and visualize drug discovery and development data. Cortellis for Informatics provides information such as published experimental pharmacology, pharmacokinetic, and pharmacodynamic results; clinical trial protocols and outcomes; competitive intelligence; patent information; and pharma company press releases and presentations.

Among other benefits, the partnership will "enable our mutual customers to integrate Thomson Reuters' authoritative content with other proprietary and public data that they have integrated via the D360 platform," according to Joseph Donahue, senior vice president at Thomson Reuters.

It will also provide D360's users with "data views that present curated public data alongside a company's internal proprietary data," Jonathan Feldmann, vice president, scientific informatics at Certara, said in a statement.

The financial details of the agreement were not disclosed.

The Scan

Should've Been Spotted Sooner

Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier.

For Martian Fuel

Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo.

To Boost Rapid Testing

The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests.

PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing

In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.